Published Online:17 Nov 2010https://doi.org/10.2217/rme.10.81
Abstract
Leading European nations with strong biotech sectors, such as the UK and Germany, are investing heavily in regenerative medicine, seeking competitive advantage in this emerging sector. However, in the broader biopharmaceutical sector, the EU is outperformed by the USA on all metrics, reflecting longstanding problems: limited venture capital finance, a fragmented patent system, and relatively weak relations between academia and industry. The current global downturn has exacerbated these difficulties. The crisis comes at a time when the EU is reframing its approach to the governance of innovation and renewing its commitment to the goal of making Europe the leading player in the global knowledge economy. If the EU is to gain a competitive advantage in the regenerative medicine sector then it must coordinate a complex multilevel governance framework that encompasses the EU, member states and regional authorities. This article takes stock of Europe’s current competitive position within the global bioeconomy, drawing on a variety of metrics in the three intersecting spheres of innovation governance: science, market and society. These data then provide a platform for reviewing the problems of innovation governance faced by the EU and the strategic choices that have to be confronted in the regenerative medicine sector.
Bibliography
- 1 Salter B, Salter C: Governing innovation in the biomedicine knowledge economy: stem cell science in the USA. Sci. Public Policy37(2),87–100 (2010).
- 2 Salter B, Harvey O: Stem cell innovation in the USA: the benefit of the minimal state. Regen. Med.3(4),597–610 (2008).
- 3 Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level. Organisation for Economic Co-Operation and Development, Paris, France (2006).
- 4 Cooke P: New economy innovation systems: biotechnology in Europe and the USA. Indust. Innov.8(3),267–289 (2001).
- 5 Levine A: Research policy and the mobility of US stem cell scientists. Nat. Biotechnol.24(7),865–866 (2006).
- 6 Martin P, Hawksley R, Turner A: The Commercial Development of Cell Therapy – Lessons for the Future?Nottingham University, Nottingham, UK (2009).
- 7 Nasto B: Chasing biotech across Europe. Nat. Biotechnol.26,283–288 (2008).
- 8 Ang S: Country-of-origin effect of VC investment in biotechnology companies. J. Commer. Biotechnol.13,12–19 (2006).
- 9 Yang W: 2009 – turning the corner. Nat. Biotechnol.28(2),116–117 (2010).
- 10 Herpin T, Karuso H, Foley JE: Australian biotech companies: navigating the maze. J. Commer. Biotechnol.11(2),110–120 (2004).
- 11 Salter B: Governing stem cell science in China and India: emerging economies and the global politics of innovation. New Genet. Soc.27(2),145–159 (2008).
- 12 Farrell D, Jensen E, Kocher B: Why Americans pay more for healthcare. McKinsey Quarterly, December (2008).
- 13 Calfee J, DuPre E: The emerging market dynamics of targeted therapeutics. Health Affairs25(5),1302–1308 (2006).
- 14 Danzon P, Furukawa M: Prices and availability of biopharmaceuticals: an international comparison. Health Affairs25(5),1353–1361 (2006).
- 15 Biotechnology Report 2006. Marks and Clerk, London, UK (2006).
- 16 Bergman K, Graff G: The global stem cell patent landscape: implications for efficient technology transfer and commercial development. Nat. Biotechnol.25(4),419–424 (2007).
- 17 Gill S: European patent law developments in stem cell research. Pathology in Practice, February (2007).
- 18 van Pottelsberghe de la Potterie B, Mejer M: The London Agreement and the cost of patenting in Europe ECORE discussion paper (2008).
- 19 Tait N: Ministers back EU patent reform plan. Financial Times, 4th December (2009).
- 20 Salter B: The global politics of human embryonic stem cell science. Global Governance13,277–298 (2007).
- 21 Paarlberg R: The great stem cell race. Foreign Policy, May–June (2005).
- 22 Abraham J, Lewis G: Regulating Medicines in Europe: Competition, Expertise and Public Health. Routledge, London, UK (2000).
- 23 Hughes-Wilson W, Mackay D: European approval system for advanced therapies: good news for patients and innovators alike. Regen. Med.2(1),5–6 (2007).
- 24 Majone G: Regulating Europe. Routledge, London, UK (1996).
- 25 Rowley E, Martin P: Barriers to commercialisation and utilisation of regenerative medicine in the UK. Nottingham University, Nottingham, UK (2009).
- 101 UK Office of Life Sciences 2010: Delivering the blueprint London, UK, Department for Business, Innovation and Skills www.bis.gov.uk/assets/biscore/corporate/docs/l/10-542-life-sciences-2010-delivering-the-blueprint.pdf
- 102 The financing of Biopharmaceutical Product Development in Europe. Study on the Competitiveness of the European Biotechnology Industry. European Commission, Brussels, Belgium (2009) http://ec.europa.eu/enterprise/sectors/biotechnology/files/docs/financing_biopharma_product_dev_en.pdf
- 103 Reviewing Community Innovation Policy in a Changing World. European Commission, Brussels, Belgium (2009) http://ec.europa.eu/enterprise/policies/innovation/files/com(2009)442final_en.pdf
- 104 EurActiv: EU unveils innovation blueprint http://www.euractiv.com/en/innovation/eu-unveils-innovation-blueprint-news-498526
- 105 Towards World-Class Clusters in the European Union: Implementing the Broad-Based Innovation Strategy. European Commission, Brussels, Belgium (2008) http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2008:0652:REV1:en:PDF
- 106 Life Sciences and Biotechnology: A Strategy for Europe. European Commission, Brussels, Belgium (2002) http://ec.europa.eu/biotechnology/pdf/com2002-27_en.pdf
- 107 Mid Term Review of the Strategy on Life Sciences and Biotechnology. European Commission, Brussels, Belgium (2007) http://ec.europa.eu/biotechnology/docs/com_2007_175_en.pdf
- 108 European Innovation Scoreboard 2009. European Commission, Brussels, Belgium (2009) www.proinno-europe.eu/page/european-innovation-scoreboard-2009
- 109 A More Research-Intensive and Integrated European Research Area. Science, Technology and Competitiveness: Key Figures Report 2008/2009. Office for Official Publications of the European Communities, Luxembourg (2008) http://ec.europa.eu/research/era/pdf/key-figures-report2008-2009_en.pdf
- 110 Burke M, Matlin S: Monitoring Financial Flows for Health Research 2008: Prioritizing Research for Health Equity. Global Forum for Health Research, Geneva, Switzerland (2008) www.globalforumhealth.org/layout/set/print/content/download/480/3028/file/s14888e.pdf
- 111 Galama T, Hosek J: US Competitiveness in Science and Technology. RAND, CA, USA (2008) www.rand.org/pubs/monographs/2008/RAND_MG674.pdf
- 112 Enzing C: BioPolis: Inventory and Analysis of National Public Policies That Stimulate Biotechnology Research, its Exploitation and Commercialisation by Industry in Europe in the Period 2002–2005. Office for Official Publications of the EU, Luxembourg (2007) http://ec.europa.eu/research/biosociety/pdf/biopolis-finalreport_en.pdf
- 113 European Human Embryonic Stem Cell Registry www.hescreg.eu/index.php?id=9
- 114 Kessler C: EU support for stem cell research. Presented at: EMA Workshop on Stem Cell-Based Therapies. London, UK, 10 May 2010 www.emea.europa.eu/docs/en_GB/document_library/Presentation/2010/05/WC500090649.pdf
- 115 Katsnelson A: US court suspends research on human embryonic stem cells. Nature Newswww.nature.com/news/2010/100824/full/news.2010.428.html
- 116 Kessler C: European policies and priorities for stem cell research. Presented at: Beyond Pattison: Challenges to Stem Cell Translation and Policy. London, UK, 7–8 May 2009 www.york.ac.uk/res/sci/events/FinalConfPres/Kessler.pdf
- 117 Science/Business Innovation Board 2008: Clustering for growth – how to build dynamic innovation clusters in Europe www.sciencebusiness.net/documents/clusterbooklet.pdf
- 118 Rozek R: Key factors in attracting internationally mobile investments by the research-based pharmaceutical industry. NERA Economic Consulting, London, UK (2007) www.nera.com/extImage/PUB_MobileInvestments_Sep2007.pdf
- 119 OECD (2008), OECD Science, Technology and Industry Outlook 2008, page 53 OECD Publishing http://dx.doi.org/10.1787/sti_outlook-2008-en
- 120 National Science Foundation: Science and engineering statistics 2008 www.nsf.gov/statistics/seind08/
- 121 The European Research Area Partnership, 2008 Initiatives. European Commission, Brussels, Belgium (2009) http://ec.europa.eu/research/era/pdf/era-partnership-2008-initiatives_en.pdf
- 122 OECD (2007) Science, Technology and Industry Scoreboard 2007, page 53 OECD Publishing www.oecd.org/document/59/0,3343,en_2649_33703_44198843_1_1_1_1,00.html
- 123 OECD (2001), International Mobility of the Highly Skilled, page 10, OECD Publishing http://dx.doi.org/10.1787/9789264196087-en
- 124 Collett E: Beyond Stockholm: overcoming the inconsistencies of immigration policy. In: European Policy Centre Working Paper 32. European Policy Centre, Brussels, Belgium (2009) www.epc.eu/documents/uploads/954588169_EPC%20Working%20Paper%2032%20Beyond%20Stockholm.pdf
- 125 SpiegelOnline: Germans reject fast-track EU immigration scheme www.spiegel.de/international/europe/0,1518,513241,00.html
- 126 Webb S, Pain E: Navigating the stem-cell research maze, science, Careers Forum Link
- 127 Beyond Borders: Global Biotechnology Report 2008. Ernst and Young, London, UK (2008) www2.eycom.ch/publications/items/biotech-report/2008/2008_EY_Global_Biotech_Report.pdf
- 128 Bioscience Innovation and Growth Team: The Review and Refresh of Bioscience 2015: A Report to Government. Bioscience Innovation and Growth Team, London, UK (2009) www.berr.gov.uk/files/file49805.pdf
- 129 Competitiveness of the European Biotechnology Industry. European Commission, Brussels, Belgium (2007) http://ec.europa.eu/enterprise/sectors/biotechnology/files/docs/biotech_analysis_competitiveness_en.pdf
- 130 Life Science Research: US a Healthy Challenger to Europe. Factsheet 1. European Commission, Brussels, Belgium (2004) http://ec.europa.eu/research/press/2004/pdf/pr_1312_factsheet1_basicresearch.pdf
- 131 IMS: Global biotech perspective www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/biotech_slides_for_internet.pdf
- 132 >Williams D, Hourd P, Chandra A: Enhancing the Competitiveness of Health Technology SMEs – Paper for the Ministerial Medical Technology Strategy Group. Loughborough University, Loughborough, UK (2008) www.advisorybodies.doh.gov.uk/hitf/mmtsg-20May09-SME%20industry%20study.pdf
- 133 Edery E: Market divergence softens growth. World Pharmaceuticals Frontiers (March 2008) (Global Trade Media) www.worldpharmaceuticals.net/editorials/013_march08/013_market.pdf
- 134 Office of Fair Trading: The pharmaceutical price regulation scheme: an OFT market study. HMO London, UK (2007) www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf
- 135 OECD (2006), OECD Biotechnology Statistics – 2006, page 46, OECD Publishing http://dx.doi.org/10.1787/9789264015821-en
- 136 OECD (2009), OECD Biotechnology Statistics 2009, page 71, OECD Publishing http://dx.doi.org/10.1787/9789264073937-en
- 137 European Patent Office www.epo.org/
- 138 Gaskill G: Europeans and Biotechnology in 2005: patterns and trends. Eurobarometer 64.3 (2006) http://ec.europa.eu/research/press/2006/pdf/pr1906_eb_64_3_final_report-may2006_en.pdf
- 139 Burger S: Overview of regulations and standards for cell therapy: an international perspective www.ac-gt.com/talks/pdfs/Cell%20Therapy%20Regulations%20-%202006%20SCT%20Workshop.pdf
